OSE Immunotherapeutics Showcases Promising Phase 2 Results for UC

OSE Immunotherapeutics Presents Significant Findings on Lusvertikimab

A recent clinical abstract celebrating the induction results from the CoTikiS Phase 2 trial of anti-IL-7 Receptor Lusvertikimab in ulcerative colitis has been honored with an oral presentation at the prestigious 20th Congress of the European Crohn’s and Colitis Organization (ECCO). This achievement underscores OSE Immunotherapeutics' ongoing commitment to refining treatments for inflammatory bowel disease (IBD).

Exciting Details on Presentation at ECCO

The accepted presentation, labeled EC25-1892, boasts a compelling title: "Lusvertikimab, a first-in-class IL-7 receptor antagonist, in moderate to severe Ulcerative Colitis: results of a multicenter, randomized, placebo-controlled phase II study." This work has not only been accepted for oral presentation but has also been spotlighted as one of the Top 10 abstracts highlighted in the Congress Overview of ECCO’25.

Key Points of the Presentation

• Presentation number: OP36
• Session title: Sustainability in IBD and beyond - Session 10: Hot topics in IBD
• Date & Time: February 22, at 10:10 - 10:20 AM
• Venue: Plenary Hall / Hall B

CEO's Enthusiastic Commentary on the Trial Results

The Chief Executive Officer of OSE Immunotherapeutics, Nicolas Poirier, expressed his enthusiasm regarding this major step. He stated, “We are thrilled to present for the first time clinical efficacy and safety data from the induction study in ulcerative colitis at such a renowned scientific meeting. This gathering unites some of the globe's leading experts in IBD. Lusvertikimab uniquely acts as an interleukin-7 receptor antagonist, exclusively blocking IL-7 with a distinct mechanism and a favorable tolerance profile.”

Understanding the Mechanism of Action

Lusvertikimab serves as a distinctive antagonist of the IL-7 receptor, particularly targeting CD127, the alpha chain of this receptor. This specialized action guides the selective inhibition of IL-7 while leaving TSLP (Thymic Stromal LymphoPoietin) unharmed. As a result, it effectively obstructs pathogenic memory and effector T lymphocytes that exhibit high CD127 levels, while concurrently promoting the function and development of regulatory T cells (Tregs) that exhibit lower CD127 levels.

Ulcerative Colitis: A Growing Health Concern

Ulcerative colitis remains a chronic condition impacting the large intestine, characterized by inflammation and ulceration. This debilitating disease results from an overactive immune response, affecting millions globally. Despite available treatment options, remission rates linger only around 25-30%, leaving many patients lacking effective therapeutic solutions. Approximately 15% of patients fail to react to any therapies and are consequently advised to consider surgery as a last resort.

About OSE Immunotherapeutics

Operating with a passion for innovation, OSE Immunotherapeutics is a biotechnology company devoted to pioneering first-in-class therapies in immuno-oncology (IO) and immuno-inflammation (I&I). The company’s collaboration with top-tier academic institutions and biopharmaceutical companies aims to create and launch transformative medicines designed to address the pressing healthcare challenges faced today and in the future. The headquarters are strategically situated between Nantes and Paris, and the company is publicly listed on Euronext.

Frequently Asked Questions

What is Lusvertikimab?

Lusvertikimab is an anti-IL-7 receptor monoclonal antibody developed by OSE Immunotherapeutics, aimed at treating moderate to severe ulcerative colitis.

What data was presented at the ECCO Congress?

The presentation highlighted promising results from the multicenter, randomized, placebo-controlled Phase 2 study on the clinical efficacy and safety of Lusvertikimab.

Why is the IL-7 receptor important?

The IL-7 receptor plays a crucial role in the survival and function of T lymphocytes, which are critical for the immune response and can contribute to inflammation in conditions like ulcerative colitis.

How does OSE Immunotherapeutics approach drug development?

OSE utilizes a collaborative model, partnering with leading institutions to develop innovative therapies addressing unmet medical needs in immuno-oncology and immuno-inflammation.

What are the next steps for OSE Immunotherapeutics after the ECCO presentation?

The company will continue its clinical trials and development of Lusvertikimab, seeking regulatory approval to offer new treatment options for patients with ulcerative colitis and potentially other inflammatory diseases.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.